4 Low-Debt Pharmaceutical Stocks Backed By Analysts

Looking into how a company finances growth can tell you a lot about the management and outlook. When a company keeps the debt reined in, using it only frugally and responsibly, it shows that there are other sound sources of funding such as profits and reserves that have been accessed to fuel growth initiatives. With this in mind, we looked for stocks in the pharmaceutical category where debt has been kept to a minimum. The companies that made our cut have also been recently reviewed by analysts and given "Buy" or "Strong Buy" ratings. See the list below to learn more about these pharmaceutical stocks.The Long Term Debt/Equity Ratio is a variation of the traditional debt-to-equity ratio; this value computes the proportion of a company's long-term debt compared to its available capital. By using this ratio, investors can identify the amount of leverage utilized by a specific company and
... Read the rest at SeekingAlpha.com